Skip to content
RCUSArcus Biosciences, Inc.

Earnings

When Arcus Biosciences, Inc. reports, what it reported each quarter, and how the stock took the results.

39 quarters. Mar 31, 2017 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 24, after the close

Wed, Feb 24, 2027in 98 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 8

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$225.00M
Revenue, change from a year earlier: Q3 2026 −50.0%, Q2 2026 +312.5%, Q1 2026 −12.5%, Q4 2025 −2.2%
Net income
-$106.00M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$3.00M−50.0% vs Q3 2025

Latest results

  1. Q3 2026Nov 4, 2026, after the closeThe release8.3%by the close of Nov 5
    Revenue
    $3.00M
    −50.0%
    Net income
    -$128.00M
    N/M
    EPS
    -$1.00
    N/M
    Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
  2. Q2 2026Aug 5, 2026, after the closeThe release+1.8%by the close of Aug 6
    Revenue
    $33.00M
    +312.5%
    Net income
    -$91.00M
    —
    EPS
    -$0.72
    —
  3. Q1 2026May 5, 2026, after the closeThe release0.5%by the close of May 6
    Revenue
    $7.00M
    −12.5%
    Net income
    -$128.00M
    N/M
    EPS
    -$1.02
    N/M
  4. Q4 2025Feb 25, 2026, after the closeThe release3.7%by the close of Feb 26
    Revenue
    $225.00M
    −2.2%
    Net income
    -$106.00M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · after-hoursNov 4, 202635 d10-Q$3.00M−50.0%-$1.008.3%
Q2 2026Jun 30, 2026Aug 5, 2026 · after-hoursAug 5, 202636 d10-Q$33.00M+312.5%-$0.72+1.8%
Q1 2026Mar 31, 2026May 5, 2026 · after-hoursMay 5, 202635 d10-Q$7.00M−12.5%-$1.020.5%
FY 2025
Q4 2025derivedDec 31, 2025Feb 25, 2026 · after-hoursFeb 25, 202656 d10-K$225.00M−2.2%—3.7%
Q3 2025Sep 30, 2025Oct 28, 2025 · after-hoursOct 28, 202528 d10-Q$6.00M−14.3%-$1.27+2.0%
Q2 2025Jun 30, 2025Aug 6, 2025 · after-hoursAug 6, 202537 d10-Q$8.00M−27.3%$0.002.6%
Q1 2025Mar 31, 2025May 6, 2025 · after-hoursMay 6, 202536 d10-Q$8.00M−20.0%-$1.141.4%
FY 2024
Q4 2024derivedDec 31, 2024Feb 25, 2025 · after-hoursFeb 25, 202556 d10-K$230.00M+641.9%—0.7%
Q3 2024Sep 30, 2024Nov 6, 2024 · after-hoursNov 6, 202437 d10-Q$7.00M−78.1%-$1.00+4.7%
Q2 2024Jun 30, 2024Aug 8, 2024 · after-hoursAug 8, 202439 d10-Q$11.00M−62.1%-$1.02+11.5%
Q1 2024Mar 31, 2024May 8, 2024 · after-hoursMay 8, 202438 d10-Q$10.00M−60.0%-$0.05—
Earlier years, FY 2017 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026000058
10-QAug 5, 2026000044
10-QMay 5, 2026000034
10-KFeb 25, 2026000009
10-QOct 28, 2025000116
10-QAug 6, 2025000101
10-QMay 6, 2025000063
10-KFeb 25, 2025000040
10-QNov 6, 2024000160
10-QAug 8, 2024000138

Provenance

ProvenanceData status and checks

Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR